| Q43833293 | A pharmacoepidemiological assessment of the effect of statins and fibrates on fibrinogen concentration |
| Q40818460 | A prospective study of fibrinogen and risk of myocardial infarction in the Physicians' Health Study |
| Q41996464 | Bezafibrate lowers plasma lipids, fibrinogen and platelet aggregability in hypertriglyceridaemia. |
| Q41445502 | Bezafibrate. An update of its pharmacology and use in the management of dyslipidaemia |
| Q36067954 | Drugs affecting plasma fibrinogen levels |
| Q40716176 | Influences of lipid-modifying agents on hemostasis |
| Q35168207 | Lipid lowering drugs |
| Q46602143 | Lovastatin Alters Blood Rheology in Primary Hyperlipoproteinemia: Dependence on Lipoprotein(a)? |
| Q40923118 | New approaches to the prevention of atherosclerosis |
| Q41560071 | Pharmacological approaches and strategies for therapeutic modulation of fibrinogen |
| Q51572977 | Postprandial hemorrheology and apolipoprotein B metabolism in patients with familial hypertriglyceridemia. |
| Q72554556 | Safety and efficacy of lifibrol upon four-week administration to patients with primary hypercholesterolaemia |
| Q34358043 | Simvastatin in severe hypercholesterolaemia: a placebo controlled trial |
| Q36331473 | The possible role of hemorheology in atherothrombogenesis |
| Q44204907 | Treatment with cerivastatin in primary mixed hyperlipidemia induces changes in platelet aggregation and coagulation system components |